Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025.The company will host a conference call to discuss fi ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.In fact, demand for these drugs has been so strong that it even surpassed supply until the drugmakers took action to scale up manufacturing capacit ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.88%. At the same time, the Dow added 1.24%, and the tech-heavy Nasdaq gained 0.65%.The the stock of company has fallen by 22.85% in the past month, lagging the Medical sector's loss of 0.32% and the S&P 500's gain of 1.17%.Analysts and investors alike will be keeping a close eye on the performance of Viking ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polyp ...

This is a high-risk, high-reward stock.In this video, I will cover the recent updates regarding Viking Therapeutics (VKTX 0.56%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Jan. 3, 2025. The video was published on Jan. 4, 2025. ...

Market Dynamics - Viking Therapeutics' share price declined by 24% in December 2024 due to intensified competition in the pharmaceutical market [1] - Merck entered into a licensing deal with Hansoh Pharma for an investigational weight-loss drug HS-10535, posing a threat to Viking's VK2735 program [3] - The weight-loss drug market is highly lucrative with only two GLP-1 drugs approved in the US, indicating significant growth potential [6] Competitive Landscape - Merck secured exclusive global licensing rights to HS-10535, committing $112 million upfront and up to $1.9 billion in milestone payments and royalties [5] - Viking's VK2735, an oral obesity drug, is relatively advanced in development and has shown promising results in clinical trials [3][8] - VK2735 has a competitive advantage over injectable treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound [4] Development Progress - HS-10535 is still in development and its efficacy remains uncertain, while VK2735 is closer to commercialization [7][8] - Viking's VK2735 is positioned as a potential go-to treatment due to its oral administration format [8]

It's been an excellent year for Viking Therapeutics (VKTX 2.19%), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February. And although it's down from the all-time highs it hit earlier this year, it remains one of the better performers in the industry over the past 12 months.However, Viking's shares recently dropped massively -- by more than 10% -- in one day. And the stock is down 24% in the past month. What exactly caused this recent decline? Should in ...

Core Insights - Viking Therapeutics has $930.4 million in cash and equivalents, providing a buffer against current spending rates, while Merck's established revenue from commercialized medicines allows it to endure clinical setbacks longer if necessary [1] - Viking's VK2735 oral candidate may have a competitive edge in the market for about a year before facing Merck's product, with clinical data suggesting VK2735 could be more effective for weight loss compared to competitors from Eli Lilly and Novo Nordisk [2][4] - The market for anti-obesity drugs is still growing and not saturated, making competition less intimidating for Viking [2] Company Developments - Viking's VK2735 is being developed in both injectable and oral formats, with the injectable version advancing to phase 3 trials after successful phase 2 results, while the oral version is in planning for phase 2 [6][7] - Viking's stock fell 18% following Merck's announcement of a licensing deal for a competing weight-loss drug, HS-10535, which includes an upfront payment of $112 million and potential milestone payments of up to $1.9 billion [9][15] - Despite the stock drop, Viking is not in immediate trouble, as the market's reaction is based on assumptions about the outcomes of its upcoming clinical trials [14] Market Context - The anti-obesity drug market is becoming increasingly competitive, with Merck's entry posing a challenge to smaller companies like Viking that have yet to establish a self-sustaining revenue model [16] - If VK2735 is successful, it could generate over $1 billion in sales within its first year, significantly benefiting shareholders [13] - The competitive landscape suggests that while Viking faces a formidable opponent in Merck, it still has opportunities to succeed if it can capitalize on its clinical trial results [18]

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period as a result.Merck makes a moveThat news hit the headlines on Wednesday, with global pharmaceutical company Merck announcing that it had entered into an exclusive worldwide licensing arrangement for a GLP-1 obesity drug currently in development ...

Company Overview - Viking Therapeutics (VKTX) shares fell 18% following Merck's announcement of entering the obesity market through a licensing deal with Hansoh Pharma for a weight-loss drug [1][5] - Merck secured exclusive rights to develop and market HS-10535, a preclinical oral small-molecule GLP-1 receptor agonist targeting metabolic disorders, including obesity, with an upfront payment of $112 million and potential milestone payments of up to $1.9 billion [2][6] Competitive Landscape - Merck's entry into the obesity space is perceived as a significant competitive threat to smaller biotech firms like Viking, which has been developing VK2735, a dual GLP-1 and GIP receptor agonist for obesity treatment [4][5] - The likelihood of Merck acquiring smaller companies like Viking has decreased, diminishing Viking's speculative value as a takeover target [6] Market Dynamics - The obesity market is projected to reach $100 billion in the United States by 2030, with major players like Eli Lilly and Novo Nordisk leading the market with their drugs Zepbound and Wegovy [12] - Other companies, including Amgen and Roche, are also making strides in the obesity drug development space, with Amgen reporting significant weight loss results from its GLP-1 therapy MariTide [13][14] Development Pipeline - VK2735 has shown promising results in clinical studies, with patients losing up to 8.2% of body weight after 28 days of treatment [9] - Viking plans to meet with the FDA before the end of 2024 to discuss late-stage study designs for VK2735 and intends to file an IND application for a new obesity drug candidate next year [10][11]